Latest Biotech News

Researchers in Gene Therapy reported that adenine base editing can rescue a cryptic splice mutation in cardiac Fabry disease–relevant cells. The study details correction of an IVS4+919 G>A...

Three gene therapy pioneers behind the first U.S.-approved gene therapy received the Breakthrough Prize in Life Sciences, recognizing foundational work that helped move gene transfer from concept...

A clinical trial reported in the journal Nature-backed release indicates regulatory dendritic cells (DCreg) can enable earlier withdrawal of standard immunosuppressive drugs in living-donor liver...

Roche announced a further global Phase III trial route for its Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec) as it seeks EMA approval progress. The company said...

Kailera Therapeutics priced an upsized IPO, raising $625 million to fund clinical development of obesity drugs, according to the company’s public offering terms. The deal sets a new benchmark for...

Biopharma investment activity showed a mix of workforce and funding signals, with fewer layoffs than the prior year but a still-elevated number of affected employees. In Q1 2026, BioSpace tallies...

Neomorph secured a $100 million Series B financing to advance NEO-811, an oral molecular glue degrader designed to degrade ARNT (HIF-1β) in clear cell renal cell carcinoma. The financing led by...

Takara Bio and Resistomap expanded a partnership to develop high-throughput antimicrobial resistance surveillance products using environmental samples. The companies combined Takara Bio’s...

Researchers reported wearable sensor technology designed to distinguish walking and non-walking behaviors as a measurable marker of Parkinson’s progression, aiming to improve early to mid-stage...

A new adenine base editing strategy reported in Gene Therapy corrected a splice mutation (IVS4+919; G>A) linked to cardiac-type Fabry disease in cells. The work centers on using ABE to restore the...

Roche said it is escalating its push for EMA approval of its Duchenne muscular dystrophy gene therapy, Elevidys (delandistrogene moxeparvovec), by announcing a further global Phase 3 trial. The...

Teams at the University of Pittsburgh and UPMC reported results from a first-in-human approach that trains the immune system to accept donor livers. The program uses donor-specific immune...

UCB agreed to buy Neurona for up to $1.2 billion, aiming to expand beyond its small-molecule epilepsy portfolio into seizure cell therapy. UCB said the deal helps diversify its pipeline with a...

Kailera Therapeutics priced an upsized IPO to raise $625 million, positioning it among the largest U.S. biotech debuts and funding a pipeline of injectable and oral obesity candidates licensed...

Neomorph closed a $100 million Series B to advance its lead molecular glue degrader, NEO-811, through a Phase I/II study. The oral therapy is designed to induce targeted degradation of ARNT...

Transformative Biotech unveiled plans built around extraction-free PCR chemistry designed to remove one of the main bottlenecks in molecular testing. The company says its patented buffer chemistry...

Beeline Medicines launched with five programs licensed from Bristol Myers Squibb and secured a $300 million Series A led by Bain Capital. Its lead asset, afimetoran, is a once-daily oral selective...

New BioSpace tallies show fewer biopharma layoffs or projected cuts in Q1 2026 versus Q1 2025, though total affected employees increased, driven largely by Viatris’ plan to reduce up to 10% of its...

FDA is moving toward easing restrictions on certain compounded peptides after signaling it will convene outside advisers to reassess whether some U.S. pharmacies should be allowed to manufacture...

Kailera Therapeutics priced an upsized U.S. IPO to raise $625 million, positioning the company among the largest-ever biotech debuts while funding a pipeline of injectable and oral obesity...